Article thumbnail

Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies

By Helen Tomkinson, John Kemp, Stuart Oliver, Helen Swaisland, Maria Taboada and Thomas Morris
Topics: Research Article
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:3070638
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2006). A: ZD4054, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma cell proliferation. Exp Biol Med (Maywood)
  2. (2007). A: ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo. Mol Cancer Ther
  3. (1996). Acute renal failure.
  4. (2002). Agency: ICH harmonised tripartite guideline; Guideline for good clinical practice E6(R1).
  5. (1964). Association (WMA). Declaration of Helsinki: Ethical principles for medical research involving human subjects. Adopted by the 18th WMA General Assembly,
  6. (2002). Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics.
  7. (2005). CC: Renal failure associated with cancer and its treatment: an update.
  8. (1994). Clearance of circulating endothelin-1 by ETB receptors in rats.
  9. (2010). CN: Castration-resistant prostate cancer: current and emerging treatment strategies. Drugs
  10. (2003). Endothelin inhibition: novel therapy for prostate cancer.
  11. (2009). Endothelin receptors as therapeutic targets in castrationresistant prostate cancer. Eur Urol Suppl
  12. (2003). FDA Guidance for industry: Pharmacokinetics in patients with impaired hepatic function: Study design, data analysis and impact on dosing and labeling.
  13. (1998). FDA Guidance for industry: Pharmacokinetics in patients with impaired renal function: Study design, data analysis and impact on dosing and labeling.
  14. (1976). Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron
  15. (2007). MS: The risk of renal impairment in hormonerefractory prostate cancer patients with bone metastases treated with zoledronic acid. Cancer
  16. (2004). PG: Endothelin receptors as novel targets in tumor therapy.
  17. (2010). Pharmacokinetic and tolerability profile of once-daily zibotentan (ZD4054) in Japanese and Caucasian patients with hormone-resistant prostate cancer.
  18. (2009). R: A phase I study of zibotentan (ZD4054) in patients with metastatic, castrateresistant prostate cancer. Invest New Drugs
  19. (1995). Simons JW: Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med
  20. (2009). Specific endothelin-A receptor antagonism for the treatment of advanced prostate cancer.
  21. (2007). Swaisland H: Metabolism of [ 14C]-ZD4054 in healthy volunteers.
  22. (1998). T: Endothelininduced apoptosis of A375 human melanoma cells.
  23. (2010). Tabesh M: Role of targeted therapy in the treatment of advanced prostate cancer.
  24. (2009). Taboada MT: In vitro metabolism of the specific endothelin-A receptor antagonist ZD4054 and clinical drug interactions between ZD4054 and rifampicin or itraconazole in healthy male volunteers. Xenobiotica
  25. (2004). The European Agency for the evaluation of medicinal products: Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function.
  26. (2004). The European Agency for the evaluation of medicinal products: Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with impaired renal function.
  27. (1995). Tozer TN: Clinical Pharmacokinetics: Concepts and Applications.
  28. (1973). Transection of the oesophagus for bleeding oesophageal varices.
  29. (2008). W├╝lfing P: Targeting the endothelin system: novel therapeutic options in gynecological, urological and breast cancers. Expert Rev Anticancer Ther